| Literature DB >> 30304153 |
Olivia de Freitas Mendes Martins1,2, Cauby Maia Chaves Junior3, Rowdley Robert Pereira Rossi4, Paulo Afonso Cunali5, Cibele Dal-Fabbro6, Lia Bittencourt7.
Abstract
INTRODUCTION: Occlusal side effects or development of pain and/or functional impairment of the temporomandibular complex are potential reasons for poor compliance or abandonment of mandibular advancement splints treatment for snoring and obstructive sleep apnea.Entities:
Mesh:
Year: 2018 PMID: 30304153 PMCID: PMC6150709 DOI: 10.1590/2177-6709.23.4.045-054.oar
Source DB: PubMed Journal: Dental Press J Orthod ISSN: 2176-9451
Figure 1Flow diagram of selection process.
Summary of descriptive characteristics of included studies
| Author (year) | Method | MAS | Subjects | Control | Follow-up period | MAS Use | Side effects summary | ||
| Type | Protrusion | Type | n | ||||||
| Doff et al. | Cephalometry | Thornton Adjustable Positioner (TAP®) | 79 ± 20% of maximum protrusion | OSA | 31 | CPAP | 2.3 ± 0.2 year | > 6 nights/week | Overbite and overjet decreased; retroclination of the upper incisors and proclination of the lower incisors; lower and total anterior facial height increased significantly; no changes in skeletal variables were found |
| Doff et al. | Clinical measurements (RDC/TMD) and questionnaire | Thornton Adjustable Positioner (TAP®) | 76 ± 25% of maximum protrusion | OSA | 51 | CPAP | 2 months, 1 year and 2 years | 6.7 ± 0.6 nights/week | OA therapy results in more pain-related TMDs in the initial period of use, compared with CPAP therapy |
| Doff et al. | Dental plaster study models | Thornton Adjustable Positioner (TAP®) | 79 ± 19% of maximum protrusion | OSA | 51 | CPAP | 2.3 ± 0.2 year | 6.9 ± 0.4 nights/week | Decreased overjet/overbite, anteroposterior change in the occlusion, decreased number of occlusal contact points in the posterior region |
| Ringqvist et al. | Cephalometry | Non- adjustable | 50% of maximum protrusion | OSA | 27 | Uvulopala-topharyn-goplasty | 4.1 year (4.0 - 4.2) | 6.1 nights/week | Changes in vertical positions of the maxillary incisors and the mandibular incisors, posterior rotation of the mandible; overjet and overbite did not change significantly |
| Robertson et al. | Cephalometry | Non- adjustable | 75% of maximum protrusion | OSA/ snoring | 100 | Pre-MAS therapy | 6, 12, 18, 24 and 30 months | > 5-6 hours/nights 7 nights/week | Changes in face height, the position of the mandible, overjet, and overbite occurred as early as 6 months. Over-eruption of the maxillary first premolars and mandibular first molars and proclination of the mandibular incisors were not evident for at least 2 years. |
| Tegelberg et al. | Clinical examination (Helkimo; Eichner index of occlusal support zones) | Non- adjustable | 50% of maximum protrusion | OSA | 37 | Uvulopala-topharyn-goplasty | 1 year | 6 nights/week | Few adverse events in the stomatognathic system or other complications |
Risk of bias assessment.
| Characteristic | Study | ||
| Doff et al, | Doff et al, | Doff et al, | |
| Sequence generation (selection bias) | Unclear | Unclear | Unclear |
| Allocation concealment (selection bias) | Unclear | Unclear | Unclear |
| Blinding of participants and personnel (performance bias) | High: performance bias due to knowledge of the allocated interventions by participants and personnel during the study | High: performance bias due to knowledge of the allocated interventions by participants and personnel during the study | High: performance bias due to knowledge of the allocated interventions by participants and personnel during the study |
| Blinding of outcome assessment (detection bias) | Low: one blinded observer performed all tracings | Unclear: unclear if outcome assessor was blinded | Low: one blinded observer performed twice all measurements |
| Incomplete outcome data (attrition bias) | Low: reasons for withdrawals were both reported and balanced across groups | Low: reasons for withdrawals were both reported and balanced across groups | Low: reasons for withdrawals were both reported and balanced across groups |
| Selective outcome reporting (reporting bias) | Low: pre-specified outcomes were reported | Low: pre-specified outcomes were reported | Low: pre-specified outcomes were reported |
| Other sources of bias | High: inter- and intraobserver reliability measurements were not carried out | Unclear | Unclear |
| Overall risk of bias | High | High | High |
| Characteristic | Study | ||
| Ringqvist et al, | Robertson et al, | Tegelberg et al, | |
| Sequence generation (selection bias) | Unclear | Unclear | Unclear |
| Allocation concealment (selection bias) | Unclear | Unclear | Unclear |
| Blinding of participants and personnel (performance bias) | High: performance bias due to knowledge of the allocated interventions by participants and personnel during the study | High: performance bias due to knowledge of the allocated interventions by participants and personnel during the study | High: performance bias due to knowledge of the allocated interventions by participants and personnel during the study |
| Blinding of outcome assessment (detection bias) | Unclear: unclear if outcome assessor was blinded | Unclear: unclear if outcome assessor was blinded | Unclear: unclear if outcome assessor was blinded |
| Incomplete outcome data (attrition bias) | High: large number of patients lost to follow up (33% in MAS group) | Low: no missing outcome data | Low: reasons for withdrawals are both reported and balanced across groups |
| Selective outcome reporting (reporting bias) | Low: pre-specified outcomes were reported | Low: pre-specified outcomes were reported | High |
| Other sources of bias | High: in the experimental (MAS) and control (UPPP) groups, some patients (10% and 27%) received both treatments | High: no control group | Unclear |
| Overall risk of bias | High | High | High |